The experimental therapy, fidanacogene elaparvovec, reduced the annualized bleeding rate of total bleeds by 71 percent. The trial compared the one-time gene therapy treatment to the current treatment for the rare blood disorder, which is a prophylaxis regimen.
Pfizer said it will share the data with regulators in 2023.
